738 related articles for article (PubMed ID: 25753670)
1. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
[TBL] [Abstract][Full Text] [Related]
2. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.
Yadava RS; Yu Q; Mandal M; Rigo F; Bennett CF; Mahadevan MS
Hum Mol Genet; 2020 Jun; 29(9):1440-1453. PubMed ID: 32242217
[TBL] [Abstract][Full Text] [Related]
4. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
[TBL] [Abstract][Full Text] [Related]
5. Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
Leger AJ; Mosquea LM; Clayton NP; Wu IH; Weeden T; Nelson CA; Phillips L; Roberts E; Piepenhagen PA; Cheng SH; Wentworth BM
Nucleic Acid Ther; 2013 Apr; 23(2):109-17. PubMed ID: 23308382
[TBL] [Abstract][Full Text] [Related]
6. Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.
Michel L; Huguet-Lachon A; Gourdon G
PLoS One; 2015; 10(9):e0137620. PubMed ID: 26339785
[TBL] [Abstract][Full Text] [Related]
7. RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy.
Sobczak K; Wheeler TM; Wang W; Thornton CA
Mol Ther; 2013 Feb; 21(2):380-7. PubMed ID: 23183533
[TBL] [Abstract][Full Text] [Related]
8. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
[TBL] [Abstract][Full Text] [Related]
9. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy.
Ho TH; Savkur RS; Poulos MG; Mancini MA; Swanson MS; Cooper TA
J Cell Sci; 2005 Jul; 118(Pt 13):2923-33. PubMed ID: 15961406
[TBL] [Abstract][Full Text] [Related]
10. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
[TBL] [Abstract][Full Text] [Related]
11. Expanded CUG repeats in
van Cruchten RTP; Wieringa B; Wansink DG
RNA; 2019 Apr; 25(4):481-495. PubMed ID: 30700578
[TBL] [Abstract][Full Text] [Related]
12. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
[TBL] [Abstract][Full Text] [Related]
13. Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1.
De Serres-Bérard T; Ait Benichou S; Jauvin D; Boutjdir M; Puymirat J; Chahine M
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362145
[TBL] [Abstract][Full Text] [Related]
14. A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.
Reddy K; Jenquin JR; McConnell OL; Cleary JD; Richardson JI; Pinto BS; Haerle MC; Delgado E; Planco L; Nakamori M; Wang ET; Berglund JA
Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20991-21000. PubMed ID: 31570586
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome Analysis Reveals Altered Inflammatory Pathway in an Inducible Glial Cell Model of Myotonic Dystrophy Type 1.
Azotla-Vilchis CN; Sanchez-Celis D; Agonizantes-Juárez LE; Suárez-Sánchez R; Hernández-Hernández JM; Peña J; Vázquez-Santillán K; Leyva-García N; Ortega A; Maldonado V; Rangel C; Magaña JJ; Cisneros B; Hernández-Hernández O
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33530452
[TBL] [Abstract][Full Text] [Related]
16. Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model.
Angelbello AJ; Rzuczek SG; Mckee KK; Chen JL; Olafson H; Cameron MD; Moss WN; Wang ET; Disney MD
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7799-7804. PubMed ID: 30926669
[TBL] [Abstract][Full Text] [Related]
17. Targeting nuclear RNA for in vivo correction of myotonic dystrophy.
Wheeler TM; Leger AJ; Pandey SK; MacLeod AR; Nakamori M; Cheng SH; Wentworth BM; Bennett CF; Thornton CA
Nature; 2012 Aug; 488(7409):111-5. PubMed ID: 22859208
[TBL] [Abstract][Full Text] [Related]
18. (CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
André LM; van Cruchten RTP; Willemse M; Wansink DG
PLoS One; 2019; 14(5):e0217317. PubMed ID: 31116797
[TBL] [Abstract][Full Text] [Related]
19. Stabilization of expanded (CTG)•(CAG) repeats by antisense oligonucleotides.
Nakamori M; Gourdon G; Thornton CA
Mol Ther; 2011 Dec; 19(12):2222-7. PubMed ID: 21971425
[TBL] [Abstract][Full Text] [Related]
20. HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence.
Kim DH; Langlois MA; Lee KB; Riggs AD; Puymirat J; Rossi JJ
Nucleic Acids Res; 2005; 33(12):3866-74. PubMed ID: 16027111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
